Canaccord Genuity Keeps Their Buy Rating on Insulet Corp

Canaccord Genuity analyst Kyle Rose maintained a Buy rating on Insulet Corp (NASDAQ: PODD) today and set a price target of $100. The company’s shares opened today at $86.90, close to its 52-week high of $94.26.

According to TipRanks.com, Rose is a 5-star analyst with an average return of 11.5% and a 57.8% success rate. Rose covers the Healthcare sector, focusing on stocks such as Obalon Therapeutics Inc, Zimmer Biomet Holdings, and Smith & Nephew Snats.

Insulet Corp has an analyst consensus of Strong Buy, with a price target consensus of $96.43.

See today’s analyst top recommended stocks >>

Based on Insulet Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $6.57 million. In comparison, last year the company had a GAAP net loss of $9.98 million.

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Insulet Corp. is an innovative medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Billerica, MA.